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Abstract: Phenolic compounds represent a diverse group of phytochemicals whose intake 
is associated with a wide spectrum of health benefits. As consequence of their low 
bioavailability, most of them reach the large intestine where, mediated by the action of 
local microbiota, a series of related microbial metabolites are accumulated. In the present 
review, gut microbial transformations of non-absorbed phenolic compounds are 
summarized. Several studies have reached a general consensus that unbalanced diets are 
associated with undesirable changes in gut metabolism that could be detrimental to 
intestinal health. In terms of explaining the possible effects of non-absorbed phenolic 
compounds, we have also gathered information regarded their influence on the local 
metabolism. For this purpose, a number of issues are discussed. Firstly, we consider the 
possible implications of phenolic compounds in the metabolism of colonic products, such 
as short chain fatty acids (SCFA), sterols (cholesterol and bile acids), and microbial 
products of non-absorbed proteins. Due to their being recognized as affective antioxidant 
and anti-inflammatory agents, the ability of phenolic compounds to counteract or suppress 
pro-oxidant and/or pro-inflammatory responses, triggered by bowel diseases, is also 
presented. The modulation of gut microbiota through dietetic maneuvers including 
phenolic compounds is also commented on. Although the available data seems to assume 
positive effects in terms of gut health protection, it is still insufficient for solid conclusions 
to be extracted, basically due to the lack of human trials to confirm the results obtained by 
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the in vitro and animal studies. We consider that more emphasis should be focused on the 
study of phenolic compounds, particularly in their microbial metabolites, and their power 
to influence different aspects of gut health. 
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1. Introduction 
Most of the beneficial health properties of fruit, vegetables, and whole grains have been attributed 
to bioactive non-nutritional chemical compounds commonly named phytochemicals, which include 
phenolic compounds. Plant phenols embrace a wide range of secondary metabolites that are 
synthesized from carbohydrates via the shikimate pathway, occurring as soluble conjugated 
(glycosides) and insoluble or bound forms [1]. Based on the extensive intake of these kinds of 
phytochemicals through the diet, a complex mixture of hundreds of phenolic compounds enters the 
gastrointestinal tract where they can be partially released and absorbed, or survive stomach and 
intestinal digestion and reach the colon until excretion via feces. Several studies have reported that an 
important part of the ingested phenolic compounds reaches the large intestine where it undergoes a 
series of microbial transformations that leads to the generation of related metabolites [2–4]. 
On occasion, gut microbiota has been defined as a biological reactor since it possesses powerful 
metabolic functions which include the transformation of many compounds that reach the colon. This 
activity is possible through the capacity of microorganisms to produce a huge and varied range of 
enzymes. In the particular case of phenolic compounds, their intestinal transformations include several 
steps. First, aglycones must be released to the media. For this, different classes of enzymes are needed 
to deconjugate the specific moiety associated to the molecule or, in the case of polymeric forms, to 
break phenolic polymers into individual monomers. Phenolic compounds are also strongly linked to 
some components of the food matrix, and this interaction is also disrupted by microbiota [1]. The 
released aglycones undergo subsequent microbial transformations which may include ring fission, α or 
β-oxidation, dehydrogenation, dehydroxylation, and demethylation, and these result in the generation 
of simpler related compounds. 
An overview of the bioactivity that is probably carried out by phenolic compounds in the large 
intestine is represented in Figure 1. The passage of digesta through the small intestine is estimated to 
take around 2–4 h, but the transit time increases considerably in the large intestine, extending to as long 
as 24 h or more [4,5]. This time is probably long enough to accumulate substantial amounts of phenolic 
compounds and induce metabolic and microbial changes in the gut lumen. Phenolic compounds are 
recognized antioxidants and anti-inflammatory agents which can protect intestinal cells from  
pro-oxidant and inflammatory injuries [6–8]. The presence of luminal phenolic compounds could also 
impact the metabolic profile, enhancing or inhibiting the generation of fermentation products derived 
from endogenous and dietary compounds. In turn, changes in the metabolic profile of the gut are 
sometimes associated with the modification of the shape of the intestinal inhabitants. In fact, some 
authors have associated the phenolic compounds–gut microbiota interaction with a presumable 
modulation effect, which could prevent or, indeed, restore microbiota alterations observed in disease [9,10]. 
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Figure 1. Overview of the possible implications of phenolic compounds at the gut level. 
The aim of this manuscript was to consult the information available from in vitro and in vivo studies 
to review the transformations that the non-digested phenolic compounds undergo when they reach the 
colon and the possible influence they have on the transformation of other intestinal metabolites, such 
as short chain fatty acids (SCFAs), sterols, and microbial products of non-absorbed proteins. In 
addition, their possible implications in metabolic and microbial changes as well as in antioxidant and  
anti-inflammatory effects at the gut level were also considered. 
2. Microbial Phenolic Metabolites 
Phenolic compounds are commonly classified into two main groups, flavonoids and non-flavonoids. 
In the next section we will describe the catabolism pathways and the phenolic metabolites formed 
related with the chemical structures of flavonoids and non-flavonoids. 
2.1. Flavonoids 
Flavonoids possess an aglycone skeleton of two flavonoid rings (A- and B-rings) connected by  
a heterocyclic C-ring. In foods, except for flavan-3-ols, flavonoids are normally presented as 
glycosides or organic acid conjugates. 
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The sub-class of flavan-3-ols includes the diastereomers catechin and epicatechin, and their 
corresponding gallate esters, epigallocatechin and epigallocatechin gallate. In foods, flavan-3-ols are 
present as monomers (catechin and epicatechin) or proanthocyanidins (variable attached monomers). 
To study the microbial modifications of flavan-3-ols, pure standards as well as grapes, tea, cocoa, 
berries, red wine, and their extracts have been used. The colonic catabolism of proanthocyanins 
undergoes a first degradation step resulting in the release of monomer structures with the subsequent 
hydrolysis of gallic acid from the galloylated forms [11–14]. Based on the literature, we propose the 
colonic pathways of monomeric flavan-3-ols and their corresponding gallate esters (Figure 2). The 
early appearance of simple phenolics (like catechol) suggests further degradation of gallic acid generated 
by hydrolysis of epigallocatechin gallate in the first steps of the colonic catabolism [11,12,14,15]. 
Similarly, the initial C-ring fission of flavan-3-ols (Figure 2A) produces the corresponding 
diphenylpropan-2-ol. Then, this is further converted into 5-(3′,4′,5′)-tri- and 5-(3′,4′)-dihydroxyphenyl-
γ-valerolactone in the cases of gallate esters and monomers, respectively [11,14,16]. The subsequent 
catabolism of the tri- and dihydroxyphenyl-γ-valerolactones originates different hydroxylated forms of 
phenylvaleric acid [11–15,17]. Neither trihydroxyphenylvaleric acid nor trihydroxyphenylpropionic 
acid have been described as microbial metabolites of gallate esters in in vitro fermentations. However, 
trihydroxyphenylvaleric acid was identified in human plasma [16]. Phenyl-γ-valerolactones and 
phenylvaleric acids have been described as exclusive microbial metabolites of flavan-3-ols. Their 
progressive microbial transformation releases different hydroxylated forms of phenyl (Figure 2B) and 
benzoic acids (Figure 2C), whose profile and abundance seem to depend on the particular metabolic 
activity of each individual microbiota and the composition of flavan-3-ols in the substrate [11–15,17]. 
Furthermore, other minor catabolites, such as hippuric acid, p-coumaric acid, and vanillic acid, 
homovanillic acid, homovanillyl alcohol, and 3-O-methylgallic acid have been associated with the in 
vivo colon metabolism of flavan-3-ols [11,13,16,18]. 
Flavonols are the most common phenolic compounds in foods such as red wine, apples, onions, 
beer, spices, herbs, berries, and cocoa, with quercetin, kaempferol, and myricetin being the most 
studied. During the first steps of the colonic catabolism of the aglycone forms of quercetin and 
kaempferol, the initial metabolites formed are dihydroquercetin (taxifolin) and dihydrokaempferol, 
respectively, which are further metabolized to di- and hydroxyphenylpropionic acid, respectively 
(Figure 3A) [19–23]. These metabolites then enter the catabolic route of phenyl acids (Figure 2B) and 
benzoic acids (Figure 2C) to generate minor related compounds [19,22,23]. Following the intake of 
radiolabeled quercetin-4′-O-glucoside in rats, high concentrations of hippuric acid were found in the 
jejunum/ileum, urine, and plasma [22]. Furthermore, 3′,4′,5′-trihydroxyphenylacetic acid and  
3′,5′-dihydroxyphenylacetic acid were the main microbial metabolites detected in rat feces after the 
administration of myricetin [24], probably derived from the intermediate dyhydromyricetin. However, 
the generation of quercetin from myricetin should not be discarded [25]. 
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Figure 2. Proposed colonic pathways of monomeric flavan-3-ols and their corresponding 
gallate esters. 
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Figure 3. Proposed colonic pathways of flavonols, flavanones, flavones, and hydrocinnamic acids. 
The flavanones hesperetin and naringenin are found in larger concentration in oranges, whereas 
eriodictyol is a flavanone commonly presented in aromatic herbs and nuts. Hydroxyphenylpropionic 
and phenylpropionic acids have been described as major fermentation products of eriodictyol and  
naringenin [23,26,27]. In addition, phloroglucynol was also detected in the fermentation vessels of 
naringenin [23] and eriodyctiol [28] which could be formed from the A-ring. In the case of hesperidin, 
3-(3-hydroxy-4-methoxyphenyl)propionic acid (dihydroisoferulic acid) and different hydroxylated 
forms of phenylpropionic acid have been reported as products of it colonic catabolism [27] (Figure 3B). 
Flavones, like apigenin and luteolin and their glycosides, are normally found in beer, olive oil, 
aromatic herbs, and nuts. In the same way as with the other flavonoid sub-classes, deglycosylation is 
the first microbial action. Apigenin aglycone is transformed into naringenin, whose microbial 
catabolism produces phenylpropionic acids [21,29] (Figure 3C). Luteolin undergoes an initial 
isomerization to form eriodictyol as an intermediate metabolite which is transformed to  
3-(3′,4′-dihydroxypheyl)propionic acid [21,30] (Figure 3C). In coincidence with in vitro data,  
3-(4′-hydroxyphenyl)propionic acid was the main metabolite detected in urine after the administration 
of apigenin-7-O-glucoside to human microbiota-associated rats [29]. 
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Genistein and daidzein are the most representative isoflavones and are normally present in their 
glycoside forms in soy products. The results of in vitro incubations of genistein, together with 
experiments where gnotobiotic rats were inoculated with isolated human equol-forming bacteria, have 
shown that, during the first steps of colonic catabolism, genistein, aglycone generated dihydrogenistein 
(Figure 4) which is partly converted into 5-hydroxy-equol [31,32]. After in vitro fermentation of 
genistein, Coldham et al. [33] observed that dihydrogenistein was metabolized into 6′-hydroxy-O-
demethylangolensin which, in turn, was transformed into 2-(4-hydroxyphenyl)propionic acid and 
phloroglucinol. On the other hand, daidzein aglycone can be reduced to dihydrodaidzein and then 
converted into equol or O-desmethylangolensin [31,32,34] (Figure 4). Although more than one 
bacteria has been described as an isoflavone-converter [31,32], not all humans have the capacity to 
convert genistein and daidzein into their respective microbial metabolites [35], which could indicate 
that isoflavone transformer bacteria are not common among human intestinal flora. 
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Figure 4. Proposed colonic pathways of isoflavones. 
Anthocyanins are widely dispersed throughout the plant kingdom, being responsible for red, blue, 
and purple colors. Red wine, grapes, berries, and pomegranate are examples of anthocyanin-rich 
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products. After microbial deglycosylation, ring fission of the aglycone releases two parts, one from the 
A-ring and the second one from the B-ring, which then undergo simultaneous catabolism [36,37]. 
Regarding the fission of the B-ring, both phenyl acids and benzoic acids have been reported as the 
microbial metabolites of anthocyanins (Figure 5). Gonzalez-Barrio et al. [37] proposed a complete 
colonic pathway for cyanidin including different alternative conversion pathways for the B-ring, and 
protocatechuic acid (benzoic acid) and 3-(3′,4′)-dihydroxyphenylpropionic acid (phenyl acid) were 
proposed as initial metabolites. The subsequent microbial metabolism of these initial products 
generates simpler compounds. Regarding benzoic acids, hydroxybenzoic acid has been reported to be a 
microbial metabolite of pelargonidin glucoside, protocatechuic acid of cyanidin glucoside, vanillic acid 
of peonidin glucoside, syringic acid of malvidin glucoside, methyl gallic acid of petunidin glucoside, 
and gallic acid of delphinidin glucoside [36–40]. Considering the results obtained from previous 
studies, the generation of benzoic acids prevails over that of phenyl acids (Figures 2B,C and 5). 
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Figure 5. Proposed colonic pathways of anthocyanins. 
Apart from B-ring fission, other microbial metabolites could also be generated from A-ring fission. 
The fission of ring A of anthocyanins could generate trihydroxybenzaldehyde [39,40], which could 
further be converted to phloroglucinol [37]. Due to the lack of complete information regarding the 
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description of the colonic fate of some anthocyanins, we tentatively propose alternative pathways in 
Figure 5. Obviously, the acceptance or rejection of these must be confirmed by future studies. Along 
with some of the metabolites described in in vitro studies, hippuric acid was also detected in human 
urine after the ingestion of raspberries [37]. 
2.2. No Flavonoids 
Phenolic acids, such as hydroxycinnamic and hydroxybenzoic acids, are present in numerous plant 
products. In plant tissues, phenolic acids form ether linkages with lignin through their hydroxyl groups 
in the aromatic ring and ester linkages with structural carbohydrates and proteins through their 
carboxylic group [1]. These bound phenolics survive stomach and intestinal digestion and reach the 
colon since, being the substrate to colon microbiota, cell wall fibrous materials are difficult to digest. 
Hydroxycinnamic acids are widely distributed in nature, with coffee, whole cereals, dried drupes, 
wine, berries, spices, and aromatic herbs being the richest sources. Caffeic, ferulic, and p-coumaric 
acids, as well as their tartaric and quinate esters, such as chlorogenic acid (quinate ester of caffeic 
acid), are included in this group, and their microbial degradation steps are proposed in Figure 3D. 
Chlorogenic acid underwent dihydroxylation, dehydrogenation, or ester hydrolysis as a first microbial 
transformation in simulated conditions [41]. In vitro fermentation of freeze-dried coffee confirmed the 
initial hydrolysis of chlorogenic acid into caffeic acid which later suffers degradation, with di- and 
mono-hydroxylated phenylpropionic acids the main metabolites detected [23,42]. Other metabolites, 
such as m-coumaric and hippuric acids, were detected in the urine of rats after the administration of 
chlorogenic acid [43]. As an intermediate product of chlorogenic acid, caffeic acid degradation was 
expected to produce a similar metabolic profile [43] (Figure 3D). Dihydroferulic acid (3-(3-methoxy-
4-hydroxyphenyl)propionic acid) [27,39] and 4-vinylguaiacol [44] together with minor degradation 
compounds have been described after in vitro fermentation of ferulic acid. 
On the other hand, hydroxybenzoic acids are made up of gallic acid and ellagic acid. Gallic acid is 
also part of the hydrolysable tannins’ and flavan-3-ols’ molecular structure. Its microbial 
transformation is proposed in Figure 2B, whereas the colonic fate of ellagic acid is explained in the 
following section. 
Ellagitannins are the main group of hydrolysable tannins. Particularly high concentrations of 
ellagitannins are found in muscardine grapes, pomegranates, and some berries and nuts. Intestinal 
breakdown of ellagitannins into ellagic acid was observed in vitro [2,37,45] and in vivo [46]. Ellagic 
acid is further metabolized by local bacteria, giving pentahydroxy-urolithins as the first metabolite 
which is successively dehydroxylated to tetra-, tri-, di-, and mono-hydroxy-urolithins, [2,37,45–47], as 
proposed in Figure 6A. An important person-to-person variability in the profile and amounts of 
urolithins has been observed with major urolithin A (dihydroxy-urolithin) or urolithin B (hydroxy-urolithin) 
producers, and others are incapable of producing any class of urolithins [2,3,37,45,47]. Gordonibacter 
urolithinfaciens and Gordonibacter pamelaeae were described as responsible for the transformation of 
ellagic acid into penta-, tetra-, and trihydroxyurolithin [48] and its absence could be associated with the 
inability of some individuals to produce urolithins. 
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Figure 6. Proposed colonic pathways of hydrolysable tannins, resveratrol, and lignans.  
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is the most common stilbene, present in grapes and 
wine, and it has been extensively studied. Regarding the in vitro experiments, dihydroresveratrol,  
3,4′-dihydoxy-trans-stilbene, and lunularin (3,4′-dihydroxy-bibenzyl) were described as microbial 
derivatives [49,50] (Figure 6B). Bode et al. [49] concluded that three colonic pathways of resveratrol 
can be distinguished in terms of the quantity of end products as a lunularin producer, 
dihydroresveratrol/lunularin producer, or dihydroresveratrol producer. Whereas dihydroresveratrol and 
lunularin were considered the main end products, the low amounts of 3,4′-dihydroxy-trans-stilbene 
detected seem to indicate that this product is intermediate or marginally produced by gut microbiota. 
The urine metabolic profile after an acute dose of trans-resveratrol confirmed the results found under 
in vitro fermentation [49,50]. 
Syringaresinol, pinoresinol, lariciresinol, secoisolariciresinol, and matairesinol are the most 
common lignans found in plant products. Besides being present in foods, secoisolariciresinol is a 
microbial degradation product of syringaresinol and also of lariciresinol, which, in turn, is derived from 
the microbial fermentation of pinoresinol [51,52] (Figure 6C). The final microbial products  
of secoisolariciresinol, with several intermediates, are enterodiol and its oxidized product, 
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enterolactone [53,54]. Secoisolariciresinol can also be converted to matairesinol, from which only 
enterolactone is obtained from microbial catabolism [52]. 
The phenolic alcohols, tyrosol, hydroxytyrosol and its precursors, oleuropein, and hydroxytyrosol 
acetate are the most representative compounds typically found in olives and virgin olive oil. Few 
studies have focused on the colonic pathway of these phenolic compounds. Oleuropein was transformed 
in vitro into its aglycone, elenolic acid, hydroxytyrosol, and hydroxytyrosol acetate [55,56] (Figure 7). 
Individual fermentation of tyrosol and hydroxytyrosol confirmed the low microbial metabolism of 
these compounds and their relative stability under in vitro colonic conditions [55]. An in vivo 
experiment following the administration of oleuropein to rats detected other related metabolites such as 
homovanillic acid [57]. 
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Figure 7. Proposed colonic pathways of oleuropein. 
Considering the complex colonic pathways, it is possible to conclude that the first microbial 
transformation of phenolic compounds leads to the accumulation of initial metabolites that share 
characteristics from the original compound (particularly conserving their functional groups) and are 
considered markers of an early fermentation stage. The continuous exposure of the initial metabolites 
to microbiota leads to the accumulation of final catabolites, which can be common to different 
phenolic sub-groups. An elevated accumulation of some microbial metabolites would be indicative of 
the main microbial pathways probably common to several individuals. On the contrary, those 
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metabolites present in minor concentrations or in a smaller proportion of individuals could be related 
to a specific microbiota composition capable of activating secondary metabolic pathways. 
Different profiles of metabolites observed after in vivo interventions suggest hepatic and renal 
metabolism prior to excretion via urine. Hippuric acid was the common phenolic metabolite detected 
in the largest amounts in plasma and urine after the intake of varied phenolic sources. The origin of 
hippuric acid can be through the microbial transformation of the quinic acid moiety or the hepatic 
metabolism of benzoic acids [58,59]. Nevertheless, the concentration of hippuric acid in urine 
decreased considerably after the antibiotic treatment of rats [60] and in the urine of ileostomy [11], 
suggesting an important contribution by the gut microbiota. 
 
Box 1. Models Concerning the Study of Phenolic Microbial Metabolites  
In vitro and in vivo studies have been essential for building the colonic pathways of 
phenolic compounds. Basically, in vitro studies consist of anaerobic incubations where 
phenolic compounds represent the microbial substrate and bacteria cultures, human or animal 
feces, the microbial inoculum. The phenolic substrate used in these studies may include 
pure standards [11,19,20,26,30,38,49,55], isolated compounds [36,38,45], phenolic 
extracts [12,15,38,39,45], and food or pre-digested food [2,37,42,57]. In vitro fermentation 
models have some questionable points, mainly their limited representativeness of in vivo conditions. 
For example, in vitro incubations do not include enterohepatic recirculation, colonocyte absorption, 
mucosa-associated microbiota, and changes in physiological conditions during the transit time. 
The latter point has been partly overcome with the development of modern controlled batch 
cultures called “Simulator of Human Intestinal Microbial Ecosystem” (SHIME). The sample 
circulates through different reactors that represent the ascending, transversal, and descending 
colon in which pH and temperature are continuously controlled and the growth of microbiota is in 
line with the environmental conditions and substrate availability [12,17,61]. Despite the 
mentioned limitations, in vitro studies provide valuable information regarding the phenolic 
metabolites generated by gut microbiota. Fermentations are usually performed for 24–48 h during 
which sub-samples are collected at different time-points. Time-course metabolite generation 
allows colon metabolic pathways that probably take place under in vivo conditions to be defined. 
As microbial metabolites can be absorbed by colonocytes, their in vitro identification provides a 
useful tool for identifying these phenolic metabolites in plasma and/or urine in the human 
bioavailability or dietary intervention studies. 
In vivo studies are ideal complements to the in vitro ones. Nevertheless, complex ethical issues, 
concerning the study of the phenomena occurring during human digestion, limit in situ 
observations and sample collection. In general, phenolic compounds are usually analyzed in 
fractionated blood (plasma, serum…) and urine to determine which compounds are absorbed and 
their absorption and excretion kinetics. In general, phenolic compounds are quickly absorbed, 
reaching the Cmax in plasma between 0.5 and four hours after the intake, corresponding to the 
stomach and/or small intestine absorption [16,18,37,62], whereas the colonic metabolites appear 
in plasma later, indicating their gradual colonic biotransformation and, in some cases, showing a 
second increase in the plasma concentration after 4 h [16,18]. 
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In vitro and in vivo studies have contributed enough so far to confirm the capacity of gut microbiota 
to metabolize phenolic compounds (Box 1). The degradation pathway routes involve several reactions 
in which the side chain groups and the heterocyclic C-ring of flavonoids are more likely to be used by 
microorganisms, while the benzoic ring remains intact. Depletion of phenolic compounds along with 
the increase in bacteria growth observed in in vitro fermentations could be considered good evidence 
to believe that these phytochemicals are used as carbon and energy sources. However, there are other 
reasons that can explain the utilization of phenolic compounds by gut microbiota. As xenobiotics, they 
may be degraded to reduce the toxicity that these compounds may have on resident bacteria. 
3. Impact of Diet Phenolic Compounds on Gut Microbial Fermentation Metabolites 
3.1. Short Chain Fatty Acids (SCFAs) 
SCFAs are saturated aliphatic organic acids consisting of one to six carbons, of which acetic (C2), 
propionic (C3), and butyric (C4) acids are the most abundant. SCFAs production mainly occurs in the 
proximal part of the colon, where the availability of substrates is most abundant. The majority of 
SCFAs (up to 95%) are rapidly absorbed by the colonocytes, leading to decreasing concentrations from 
the proximal to distal colon. Only a minor fraction of the SCFAs (about 5%) is excreted in the  
feces [63]. Isobutyric, isovaleric, and valeric acids, also called branched chain fatty acids (BCFAs), 
constitute the remaining 5% and are derived from the microbial fermentation of branched chain amino 
acids [64,65]. A disruption in the concentration of SCFAs, especially due to an increase in the 
proportion of BCFAs, could be a possible signal of loss of intestinal homeostasis [66,67]. 
Acetic acid, propionic acid, and particularly butyric acid have been extensively studied due to their 
involvement in the maintenance of correct body functions [68,69]. Butyric acid is considered essential 
for maintaining the colon cellular function since it is the main energy source for colonocytes [70]. 
Chemopreventive properties have also been described for butyric acid due to its capacity to prevent the 
formation of malignant cells and to induce apoptosis in colonic cancer cells [71]. In fact, lower 
amounts of SCFAs [72] and butyric acid-producing bacteria [73] were found in the feces of colorectal 
patients than in those of healthy subjects. Contrarily, elevated amounts of BCFAs are presumed to be 
prejudicial to colonic health [74,75] and high concentrations have been observed in inflammatory 
bowel diseases (IBDs) [66] and obesity [67]. 
In vitro fermentation of pure phenolic compounds enables the extent to which phenolic compounds 
and gut microbiota are exclusively involved in SCFAs production to be seen. An improvement in the 
total production of SCFAs was observed after the in vitro incubation of chlorogenic acid, rutin, caffeic 
acid, quercetin [76], and olive oil polyphenols [77]. To the contrary, isolated proanthocyanidins [78] 
and punicalagins [45] suppressed the in vitro generation of SCFAs. The increments observed leave 
interpretations open to the thought that phenolic compounds could be transformed into SCFAs. 
However, this alternative is practically discarded since the ring cleavage of the aromatic ring of 
phenolic compounds was not observed under anaerobic conditions [79]. Rather than direct production, 
the increase in SCFAs observed after in vitro fermentation of pure phenolic standards is probably 
related to a higher fermentation rate of the released glycoside moieties and/or of the remaining 
carbohydrates in the culture media or the feces. 
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Phenolic-rich extracts have increased in interest since they can provide added value as food 
ingredients and can also be used in nutraceutical applications. Their involvement in SCFAs generation 
has shown mixed results. In two experiments, black tea extract, red wine-grape juice extract [17], and 
soy germ powder [61] were studied in a SHIME in vitro system. The tea extract and soy germ powder 
increased the concentration of acetic and propionic acids, whereas the soy germ and the mix extract 
only increased the concentration of propionic acid. In parallel, a slight decrease in the amount of 
butyric acid was observed after continuous feeding of black tea and red wine-grape juice extracts.  
A rise in the production of the three main SCFAs was observed after incubation of pomegranate 
extract [45]. Higher recoveries of urolithins in the batch cultures of pomegranate extract compared 
with that of punicalagins suggest major microbial activity and a possible involvement of phenolic 
microbial metabolites. Nevertheless, rats fed with raspberry seed extract produced more SCFAs and 
minor urolithins than rats that received strawberry seed extract [80]. Thus, the results of different 
studies are contradictory and phenolic compounds with similar chemical characteristics showed 
different behavior. 
Because the later data was obtained under in vitro conditions, it risky to extrapolate the same effects 
to in vivo conditions when extracts or phenolic compounds are ingested through the diet. 
Heterogeneous data have also been obtained from animal and human studies after exposure to a 
phenolic-rich diet. The concentration of acetic acid increased in the feces of pigs after two weeks of 
receiving a diet enriched with 0.2% of green tea phenolic compounds [81]. In healthy humans, the 
inclusion of a red wine-grape juice extract, but not grape juice extract, over four weeks, reduced the 
concentration of isobutyric acid [82]. Furthermore, a decrease in the production of SCFAs in rats was 
noticed after the administration of an aqueous passion fruit leaf extract [83]. No changes in the 
production of SCFAs were observed after the inclusion of trans-resveratrol or quercetin (alone or in 
combination) in rats fed with a high-fat sucrose diet for six weeks [84] or in healthy humans after the 
intake of pomegranate juice for four weeks [85]. 
The role of non-digestible carbohydrates (dietary fiber) in the production of SCFAs is 
unquestionable. Based on its chemical and physical properties, dietary fiber is normally classified into 
soluble and insoluble. Pectin, oligosaccharides (fructooligosaccharides, FOS), and inulin are 
considered soluble fiber. The fermentability of soluble fiber is high due to its capacity for water 
solubilization, which allows the action of microbial enzymes. Insoluble fiber corresponds basically to 
cellulose, some hemicelluloses, lignin, and arabinoxylans, which are also fermented, but at a much 
lower rate than soluble fiber [86]. Many authors have postulated that the production of SCFAs may be 
enhanced when dietary fiber is administered in combination with phenolic compounds. However, this 
claim remains inconclusive. 
Replacement of part of the cellulose (maize starch) by strawberry and raspberry defatted seed 
extracts rich in ellagitannins enhanced the total SCFAs production and the proportion of butyric acid in 
rats after four weeks [80]. However, the results of the latter study were not only attributed to the 
phenolic compounds since their effectiveness was more marked in the raspberry extracts, coinciding 
with a major content of soluble fiber. In a similar experimental design, equivalent concentrations of 
dietary fiber were included in the diets of rats through soluble and insoluble fractions of bilberries, 
blackcurrants, and raspberries [87]. Rats fed with the soluble fraction of bilberries showed the highest 
caecal formation of SCFAs and fiber fermentability in coincidence with higher anthocyanin intake. 
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Moreover, the addition of apple-pomace extract, in combination with FOS and cellulose, for four 
weeks [88], or lyophilized apple together with apple pectin [89], increased the proportion of butyric 
acid in rats compared with when fiber was consumed alone, suggesting an additional benefit that could 
be attributed to the presence of phenolic compounds in the extract. 
In some cases, the combination of fiber with phenolic compounds seems not to alter the gut 
metabolism of SCFAs. For example, apple fiber rich in phenolic compounds did not produce  
any change in the generation of SCFAs, either in combination with apple pectin under in vitro 
conditions [71] or together with boysenberry juice after four weeks of human consumption [90]. In line 
with the previous studies, rats fed with apple-pomace extract rich in proanthocyanins showed no 
difference in the production of SCFAs compared with rats fed with apple-pomace extract deprived of 
phenolic compounds [91], and similar results were observed after combination of grape extract and 
inulin in the diet of rats [92]. Inhibitory effects in the production of SCFAs were observed when 
isolated apple polysaccharides were fermented in vitro together with purified apple phenolic extract 
rich in proanthocyanins [79]. Similarly, the suppression of SCFAs was also noticed in rats after four 
weeks of a combination of wheat and oat fiber with blackcurrant and chokeberry extracts (both rich in 
proanthocyanidins) [93] and low or high ellagitannin-rich strawberry extract in combination with  
FOS [94]. The conversion of SCFAs from starch was also suppressed by the addition of grape-seed 
extract to pig fecal incubations [95]. 
Since many factors such as the abundance and activity of specialized carbohydrate-fermented 
bacteria and enzyme expression and activity, as well as substrate availability, are involved in SCFAs 
synthesis, phenolic compounds could interact with one or more of these factors. Depending on the type 
and amount of the phenolic compounds ingested, they reach the colon in different proportions and 
degrees of polymerization [4,62]. In accordance with this, they could promote or inhibit the growth of 
carbohydrate-fermented bacteria [76,96]. Bacterial enzymatic expression and activity is crucial for the 
release of monomeric compounds from polysaccharides to form SCFAs. In addition, different works 
suggest that polyphenols might modulate the activity of glyosidic enzymes differently [80,92,93]. 
In plant foods, phenolic compounds are naturally associated with dietary fiber. Thus, the 
physiological effects of fiber may depend not only on its chemical and physical properties, but also on 
its particular linkage and the composition of its phenolic compounds [44,97]. The effects observed to 
be hampered, particularly by proanthocyanins, may be associated with tight bonds among fiber and 
phenolic compounds which result in a delay in degradation and, thus, less fermentation. Nevertheless,  
Snelders et al. [44] observed that fiber fermentability was more related to the amounts of phenolic 
compounds present in the fiber matrix than to their form (free or bonded to fiber). Thus, performing 
studies to define the intrinsic composition of dietary phenolics and food fiber could be of great interest 
for understanding the role of both food components when these are alone or together. 
However, it is still questionable whether it is really desirable to stimulate the production of SCFAs. 
As SCFAs also represent energy extraction of non-absorbed macronutrients, they can provide 
approximately 10% of the total energy intake [98]. This aspect is considered positive in populations 
with a diet rich in plant-derived polysaccharide food. Nevertheless, this may be detrimental in Western 
populations, because a greater capacity to harvest energy from the diet could contribute to the positive 
calorie intake balance typical of obesity [99]. In fact, the gut microbiota of obese individuals are 
especially rich in bacteria specialized in carbohydrate fermentation [99,100]. Hindering of SCFAs 
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production observed for some classes of phenolic compounds may be effective in reducing the energy 
harvest in overweight and obesity, which might partially explain the weight loss observed after the 
intake of food rich in phenolic compounds [101]. In synthesis, the versatility of phenolic compounds 
and their association with fiber, free or bound, could stimulate the design of different food products or 
recommendations depending on the effects expected to be attained. 
3.2. Bile Acids and Sterols 
Bile acids (BAs) are classified into primary and secondary. In humans, the primary BAs cholic and 
chenodeoxycholic acids are synthesized from cholesterol by hepatic enzymes and stored in the 
gallbladder (conjugated with the amino acids glycine and taurine) until being excreted into the 
duodenum to facilitate the digestion and absorption of lipophilic compounds. Most of the conjugated 
primary BAs are reabsorbed in the ileum and the remaining fraction reaches the colon, where cholic 
and chenodeoxycholic acids are metabolized into deoxycholic and lithocholic acids, respectively, by 
gut microbiota [102]. The main microbial catabolism steps include the deconjugation of amino acids 
and dihydroxylation by microbial 7-α-dehydroxylase [102,103]. 
Fecal cholesterol represents the non-absorbed dietary cholesterol in addition to that provided by 
intestinal desquamated cells. The microbial reduction of cholesterol releases coprostanol as the main 
metabolite, generating cholestanone and coprostanone as intermediates [104]. High excretion of  
sterols and their microbial metabolites through feces has been associated with hipocholesterolemic 
effects [105], but is also a common feature of high fat diets [106]. A continuous exposure to elevated 
luminal levels of secondary BAs and cholesterol microbial metabolites has been suggested to increase 
the susceptibility to intestinal inflammation and colorectal cancer [74,107–109]. In addition to the 
toxic effects of secondary sterols per se, the concentration of putrefactive compounds (see Section 3.3 
below) could also increase the lumen toxicity due to the release of amino acids (glycine and taurine), 
these being products of the microbial hydrolysis of BAs. 
There is scarce data regarding the impact of phenolic compounds on the gut microbial 
transformation of BAs and cholesterol. Different studies have demonstrated that phenolic compounds 
have suppressing effects on the microbial conversion of sterols. For example, the amount of secondary 
BAs was reduced in rats fed with a diet containing tea polyphenols and gallotannins [110] or apple, 
grape, and red beet juices [111]. In another study with rats, the supplementation of a high fat diet with 
curcumin and caffeic acid reduced the concentration of deoxycholic acid in feces, whereas the 
administration of caffeic acid, catechin, rutin, and ellagic acid reduced the amount of lithocholic  
acid [112]. However, there was no evidence of lower conversion of primary to secondary BAs when 
red wine tannins were added to rat diets [113], or when healthy humans received pomegranate juice 
over a period of four weeks [85]. Regarding sterols, it seems that dietary phenolic compounds could 
also influence the conversion of cholesterol into their respective microbial derivatives, especially 
coprostanol. Compared with a control diet, rats that received tea polyphenols and gallotannins 
increased their excretion of fecal cholesterol in detriment to the excretion of coprostanol [110]. 
Similarly, pomegranate juice intake reduces the conversion rate of cholesterol to coprostanol in healthy 
adults [85]. On the other hand, a large proportion of coprostanol was observed in rats after the intake 
of apple, grape, and red beet juices [111]. These results suggest that the conversion of primary BAs to 
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secondary BAs and cholesterol to coprostanol is hampered by phenolic-rich diets, but more data 
regarding the role of phenolic compounds on colonic sterol gut conversion in humans is needed. 
The negative implications of the secondary metabolites of sterols in the colon may be mitigated by 
phenolic luminal compounds. The inclusion of chlorogenic acid in the diet of mice reduced the 
deoxycholic acid's tumor-promoting effects [109]. In this line, protection against the cytotoxicity 
effects of deoxycholic acid in Caco-2 cells was observed when cells were incubated with 
proanthocyanidins [114]. In another in vitro study in which deoxycholic acid was incubated with  
HCT-116 cells, antigenotoxic and aticytotoxic activity was observed for quercetin, resveratrol, and 
rottlerin [115]. In the same study, genistein, curcumin, and epicallocatechin gallate showed no effect. 
High fat diets have also been associated with the increase of the activity of β-glucuronidase [106]. 
Many toxic metabolites are neutralized by glucuronide conjugation and it is the form that promotes 
their excretion from the body. Thus, deglucuronidation not only promotes the retention of toxic 
metabolites in the body but also increases gut environment toxicity. It has been also proposed that 
phenolic compounds could interfere with the activity of β-glucuronidase, but the results are 
inconsistent. A decrease in the activity of β-glucuronidase has been observed in rats after diet 
supplementation with grape extract [92] and ellagitannins in combination with cellulose [94]. On the 
contrary, higher activity of β-glucuronidase was noticed in rats after the addition of blackcurrant 
polyphenols to the diet [93]. 
To date, the effects of phenolic compounds on the microbial transformation of colonic sterols have 
not been explored in depth and there is no information about the role of phenolic microbial 
metabolites. Regarding the changes in fecal sterol composition through the effect of phenolic-rich 
products, the data available in the literature is too scarce to enable solid conclusions to be drawn. 
Sterols are a non-invasive and easy parameter to be analyzed in fecal samples with a relatively high 
sensitivity to change when the characteristics of the diet also change [106]. This converts them into 
good candidates for reflecting alterations in the gut lumen after dietary interventions, particularly those 
containing high fat. 
3.3. Products of Non-Absorbed Protein Metabolism 
Every day, variable amounts of nitrogenous compounds of dietary and endogenous origins reach the 
colon. Protein-rich diets, particularly those containing red meat, increase gut toxicity as a consequence 
of an excessive production of microbial products derived from protein fermentation [64,65,116,117]. 
These substances, also called putrefactive compounds, include ammonia, fecal phenolic (phenol and  
p-cresol) and indolic compounds (indol and skatole), sulphur compounds (hydrogen sulphide, methyl 
mercaptan, and dimethyl sulphide), branched chain fatty acids, and polyamides (putrescine, agmatine, 
cadaverine, tyramine, and histamine). Intestinal ammonia is generated through the microbial 
deamination of urea and amino acids [65,118]. Phenolic and indolic compounds are mainly derived 
from the microbial catabolism of aromatic amino acids (phenylalanine, tyrosine, and tryptophan) [65]. 
Sulphate-reducing bacteria produce sulphur metabolites as a product of anaerobic respiration during 
the catabolism of cysteine and methionine [119]. Polyamides, besides being present in food, are also 
released in the gut by the bacterial metabolism [120]. 
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Elevated undigested luminal proteins could alter the intestinal ecology, stimulating the activity  
of nitrogen-degrading bacteria, which are considered to have detrimental effects in gut  
homeostasis [121,122]. In parallel, microbial enzymatic expression and activity increase proportionally 
with the amount of substrate [122], thus promoting the accumulation of putrefactive compounds which 
are associated with gut integrity and function loss due to their potential cytotoxicity, genotoxicity, and 
carcinogenic activity, increasing the risk of inflammatory bowel disease (IBD) and the development of 
colorectal cancer [66,74,116,123]. 
The modification of dietary patterns, such as including dietary carbohydrates [89,116,117], and 
restricting energy intake [124], has shown an inverse relationship with the concentration of these 
putrefactive fecal compounds. However, there is insufficient information regarding the effects of 
phenolic compounds in this aspect. Among the limited number of studies focused on researching the 
relation between protein fermentation and phenolic compounds, the most numerous are those on 
polymeric and monomeric flavan-3-ols. In the case of animal studies, a tea phenol-enriched diet 
reduced the pH and concentration of ammonia, phenol, p-cresol, and skatole in pig feces after two 
weeks of treatment [81]. Satisfactory results were also observed in humans after supplementation with 
grape seed extract [125] and flavan-3-ols [126]. Both products reduced fecal pH and hampered the 
production of sulphur compounds. A trend toward a decrease in phenol, p-cresol, 4-ethylphenol, 
indole, and skatole in feces was observed after consumption of grape seed extract, but these 
compounds were not studied after flavan-3-ol supplementation. In the case of ammonia, its fecal 
amounts were significantly reduced in the flavan-3-ol group and tended to decrease after grape seed 
extract intake. More consistent results, observed after the intervention with flavan-3-ols, may be 
related to the duration of the study, this being two and six weeks for grape seed extract and  
flavan-3-ols treatments, respectively. On the contrary, no changes in the production of ammonia and 
sulphides were noticed after continuous feeding of soygerm powder in a SHIME system [61]. 
A reduction of the pH of the feces observed after phenolic intervention could partly explain the 
decrease in the concentration of putrefactive substances, since microbial proteases are more active at 
neutral or slightly alkaline pH [127]. However, this is not a common effect. In some cases, phenolic 
compounds increase [92] or have no effects [80,83] on lumen pH. In addition, a reduction in fecal 
putrefactive compounds does not always respond to a reduction in the pH [80,92]. The differences may 
depend on the predominant class of bacteria and the availability preference of the substrate type. For 
example, Escherichia coli and Proteus mirabilis produced ammonia from amino acids even at low  
pH [118]. 
Phenolic compounds and their microbial metabolites possibly collaborate with additional factors to 
reduce the accumulation of protein fermentation products. A reduction of protein conversion, beyond 
the decrease in pH in the gut lumen, may also be associated with the capacity of phenolic compounds 
to inhibit proteolytic bacteria and interfere with their enzymatic activity. Gram-negative Proteobacteria 
(especially E. coli), Bacillus spp., and Gram-positive Clostridia [118,128] have been implicated in gut 
proteolysis and their abundance in IBDs is probably associated with the typical morphological and 
physiological alterations [129,130]. Beside the capacity of phenolic compounds to inhibit the growth 
of several members of the proteolytic bacteria, it has been observed that phenols also possess the 
capacity to attenuate the expression of genes involved in the secretion of proteases, inhibiting their 
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synthesis and their activity [125,131–133]. The degree to which the enzymatic activity is blocked 
depends on the phenolic concentration, its molecular structure, and its functional groups [133]. 
Abnormal concentrations of proteinases and putrefactive compounds in the lumen alter the 
permeability of the gut epithelium, promoting the movement of toxic substances across the intestinal 
barrier, which leads to a tendency to activate inflammatory mediators [129,134]. One of the reported 
mechanisms by which phenolic compounds improve barrier integrity is by increasing the expression of 
tight junction proteins [84,134–137]. This may mean that although some phenolic compounds are 
unable to reduce protein fermentation, they offer an alternative way of protecting colon integrity, 
enhancing the host tolerance to susceptible molecules present in the internal environment. 
Large intestine digestion is a dynamic system in which entrapped compounds in the digesta pass 
through the ascending, transversal, and descending colon before being excreted by feces. Local 
microbiota is active throughout the lumen, metabolizing non-absorbed products in the function of 
substrate preference and availability, and is also conditioned by the physiological conditions of the gut 
(pH, redox potential, transit time) [138]. The pattern of the native phenolic compounds present in food 
change between the colonic segments due to the microbial fermentation, resulting in the accumulation 
of different metabolites with different activity than their precursors. As major proteolytic activity is  
found in the terminal colon [64,123], it would be interesting to study the interaction of microbial 
proteolysis-phenolic metabolites in this part of the gut. In addition, we have found only one paper 
related to the study of the modification of fecal nitrogen compounds after the addition of phenolic-rich 
products in a high red meat diet in humans [139]. However, to have a better understanding of the role 
of dietary phenolic compounds in protein fermentation at gut level, more human and animal studies  
are needed. 
4. Impact of Phenolic Compounds on Intestinal Function 
4.1. Intestinal Redox Homeostasis 
Oxidative stress is defined as the damage promoted by an imbalance between pro-oxidant agents 
(free radicals) and endogenous (superoxide dismutases, SOD, catalase glutathione peroxidase, GPx, 
and glutathione, GSH) and exogenous mechanisms to neutralize their effects. Free radicals are highly 
reactive molecules capable of reacting with the biological components of cellular structures, such as 
the structural lipids of cell membranes, proteins, and nucleic acids (DNA damage), compromising 
good cell function and integrity. Moreover, the alteration of cellular components caused by oxidative 
stress in many cases precedes the over-expression of pro-inflammatory agents that are responsible for 
the activation of mechanisms that trigger cell damage [140]. Repeated bouts of inflammation can lead 
to the occurrence of IBDs, such as ulcerative colitis and Crohn’s disease, which are, in turn, risk 
factors of colon cancer [141]. 
Pro-oxidant substances are products of normal aerobic metabolism, but their levels increase as a 
consequence of toxic exposure (smoke, excessive alcohol intake, irradiation, some drugs, food 
components, toxins) and other particular situations (age, infection, stress). The gastrointestinal tract 
produces, receives, and retains these types of substances, which implies an elevated risk of alterations 
in cells and tissue in situations of over-production of free radicals and/or depletion of antioxidant 
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reparative mechanisms [142]. Dietary phenolic compounds could act as an antioxidant system in the 
gastrointestinal lumen and epithelium, reducing the oxidative damage in different ways: safeguarding 
the activity of endogenous antioxidants, decreasing free radical production, or neutralizing the latter by 
radical scavenging [6,7,9,140,143–147]. 
In vitro studies using cell-based methods are considered a good tool for deciphering the 
mechanisms by which phenolic compounds attenuate oxidative responses. Treatment of intestinal 
Caco-2 cells with different fractions of cranberry and apple peel phenolic extracts [140,143], as well as 
red wine extracts [144], effectively mitigated the membrane structure disruption caused by the  
pro-oxidants Fe/ascorbate and tertra-butyl hydroperoxide, respectively. Direct scavenging activity is 
the proposal mechanism by which urolithins suppress the generation of free radicals from activated 
neutrophils [145]. On some occasions, foods also collaborate with the pro-oxidant potential of the gut 
environment. For example, an overproduction of free radicals and a reduction of GSH activity were 
evident in Caco-2 cells when they were incubated with acrylamide, but the latter effects were reduced 
by cocoa phenolic extract, procyanidin dimer B2, and epicatechin [146]. In a similar way, protection 
against oxidative damage induced by the micotoxin deoxynivaleol in HT-29 cells was also observed 
when the culture media was enriched with epigallocatechin gallate [147]. 
The main entrance route for phenolic compounds is the gastrointestinal tract, where they reach  
a greater lumen concentration and remain longer compared with those observed in blood  
circulation [22,62]. Also, the extensive phase II metabolism (glucuronidation, sulphatation, and 
methylation) that phenolic compounds undergo during absorption and body distribution created doubts 
concerning their effectiveness as antioxidant agents at the systemic level [13,145]. In the case of colon 
lumen, the non-absorbed phenolic compounds and their microbial metabolites prevail in  
native-unconjugated forms [148]. During digestion, the antioxidant capacity of the luminal content can 
indeed increase compared with the original food, probably due to the release of phenolic compounds 
from the food matrix promoted by the physiological conditions and action of digestive enzymes [149]. 
In the large intestine, microorganisms have the ability to release those phenolic compounds intimately 
entrapped in the food matrix (particularly dietary fiber), which also contribute to the total antioxidant 
capacity at the gut lumen level [150,151]. Moreover, the phenolic compounds released from the 
digestive bolus can be distributed into intestinal fluids and favor direct contact with the colonic 
epithelium, mitigating the detrimental effects of free radicals at the cell level. 
The antioxidant status in in vivo studies (animals or humans) could be estimated by analyzing the 
antioxidant capacity of the intestinal content or fecal water by different methods, such as the oxygen 
radical absorbing capacity (ORAC), the ferric reducing antioxidant power (FRAP), the diphenyl-1-
picrylhydrazyl (DPPH), the free radical scavenger (TBARS), and the 2,2′-azinobis-(3-
ethylbenzothiazoline-6-sulphonate) radical cation (ABTS) [6,13,14,19,20,149–151]. The total 
antioxidant capacity of the intestinal content increased after the ingestion of grape seed extract in  
rats [151] and limited the production of free radicals in human fecal water after polyphenol-rich 
chocolate intake [152]. In contrast, some studies have noted no changes in the antioxidant capacity in 
colon tissue after the intake of phenolic-rich products [10]. The difference in the bioactivity between 
microbial phenolic metabolites and their parent compounds together with the progressive decrease of 
the lumen phenolic concentration due to the active colonic absorption could be an explanation for the 
unobserved antioxidant effects. However, it should be stressed that lack of effect in the total 
Molecules 2015, 20 17449 
 
 
antioxidant capacity does not necessarily encompass the loss of other biological properties [10] (see 
next Section 4.2.). 
4.2. Intestinal Inflammation 
Inflammation is a biological phenomenon associated with the innate body immune response in the 
first line of defense to combat threats which could compromise human health. Episodes of controlled 
inflammation are indispensable for suppressing chemical, biological, and physical injuries. However, 
in some cases, due to diverse genetic and environmental causes, uncontrolled inflammation responses 
predispose individuals to the development of chronic diseases. In the case of the gastrointestinal tract, 
IBDs are characterized by an unknown etymology of recurrent episodes of inflammation  
causing a progressive loss of cellular function and tissue degeneration that could develop into colon 
cancer [141,153]. 
The chronification of inflammation involves complex and interconnected mechanisms of molecular 
mediators, whose continued feedback promotes the perpetuation of inflammation. The over-production 
of free radicals (reactive oxygen and nitrogen species) and cytokines (TNF-α, IL-6, IL-8, PGE2, among 
the most studied), the up-regulation of nuclear factor kappa-B (Nf-κB) and monophosphate-activated 
protein kinase (MAPK), and the recruitment, activation, and adhesion of leukocytes have been 
identified as occurring in IBDs [7,8]. Phenolic compounds seem to inhibit or attenuate the intensity of 
the inflammatory response by modulating the cellular inflammatory mediators and/or neutralizing free 
radicals (see Section 4.1 above). 
In vitro cultures of intestinal cells are particularly valuable models for identifying the target 
molecules involved in chronic inflammation which may be susceptible to regulation by phenolic 
compounds. The results obtained from these studies could be interesting for the design of new  
anti-inflammatory drugs capable of avoiding the adverse side effects observed for some drugs used to 
treat IBDs [154]. The possible mechanisms by which phenolic compounds could mitigate or suppress 
inflammatory responses in vivo can be predicted by cells activated by different types of inflammation 
promoters. The down-regulation of NF-κB is considered a therapeutic target in IBDs, since it prevents 
the activation of pro-inflammatory mediators, such as COX-2 and iNOS, which, in turn, are 
responsible for the production of cytokines and free radicals. Individual compounds, such as 
epigallocatechin gallate [147] and anthocyanins [155], and also phenolic mixtures obtained from apple 
peels [143], cocoa [8], cranberries [140], and red wine [156], have shown an in vitro ability to inhibit 
the activation of NF-κB pathways. In the latter studies, the inhibition of NF-κB activity was  
also associated with the down-expression of COX-2 [8,143,147,156] and iNOS [8,140,156]. 
Resveratrol [157] and cocoa phenolic compounds [146] were also effective as regulators of other 
signaling pathways such as JAK-STAT and MAPK, respectively. On the contrary, chlorogenic-rich 
fractions obtained from lyophilized blueberries did not show clear evidence as inhibitor agent of  
NF-κB [155]. 
Although less common compared with the data available regarding the anti-inflammatory potential 
of phenolic compounds, it seems that their microbial metabolites also possess similar properties. The 
down-regulation of COX-2 in human adenoma cells was observed after the incubation of  
(3′,4′-dihydroxyphenyl)acetic and 3-(3′,4′-dihydroxyphenyl)propionic acids [158], common phenolic 
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catabolites detected in feces. Reclusion and adhesion of leukocytes play an important role in the 
development of inflammation since they also secrete pro-inflammatory cytokines. The secretion of 
cytokines TNF-α and IL-6 was effectively inhibited by urolithins after activation of THP-1 human 
monocyte cells [159]. Urolithins were also effective as anti-inflammatory mediators in activated 
neutrophils, inhibiting cytokines and the secretion of the proteinases necessary for adhesion [145]. 
Fibroblasts are a type of cell that synthesizes the extracellular matrix and collagen, responsible for 
tissue cicatrization. Their activation, mediated by cytokines, monocytes, and free radicals, also 
involves the secretion of pro-inflammatory agents. In addition, the exacerbated extracellular 
production of collagen could lead to intestinal stenosis (bowel obstruction) [160]. Urolithins, 
especially urolithin A, were also effective at inhibiting the activation, migration, and adhesion of colon 
fibroblasts with a concomitant reduction of several secretory pro-inflammatory mediators. These 
effects were even more evident than those shown by their precursor, ellagic acid [161]. 
Chemically induced IBD in animals is a revolutionary approach to studying the effect of phenolic 
compounds on inflammation under in vivo conditions [153]. The improvement in physical indicators 
(less body weight loss) and hematological and histological probes, together with a reduction in the 
expression of pro-inflammatory mediators in combination with phenolic treatment, constitute evidence 
of the protection given by phenolic compounds against intestinal epithelium damage and the 
attenuation of the inflammatory response. Individual phenolic compounds [7,10,134,136,162], and 
phenolic extracts [7,8,163,164] have shown positive effects in the control of IBDs in animals, even to 
the same extent as sulphosalizine, a common medicine used in IBDs, but with fewer collateral  
effects [7]. Contrary to the later results, the administration of resveratrol to rats for six weeks induces 
the expression of inflammatory parameters [84]. Data from animal studies support the  
anti-inflammatory effect of phenolic compounds observed in in vitro experiments, but the role of 
phenolic metabolites in this aspect is still unclear, due to the lack of information about the phenolic 
disposition in tissues and feces in most of the later studies. 
Dietary intervention in human studies including IBD patients is basically conducted to observe the 
remission of clinical symptoms or the diminution in the number or intensity of relapses [165–167]. 
Despite phenolic compounds have been extensively studied in animal models of IBDs, data regarding 
human trials is currently limited to one study in which the administration of epigallocatechin gallate to 
patients with ulcerative colitis over 56 days showed a satisfactory degree of remission of symptoms 
with minimal side effects [166]. Due to the ethical issues mentioned above, human studies to 
investigate the in situ effects promoted by phenolic compounds are not always possible. Nevertheless, 
there are promising fecal inflammatory markers that could potentially be used in human studies with 
minimal invasiveness. 
Calprotectin and lactoferrin are binding proteins found in the cytoplasm of neutrophils, monocytes, 
and macrophages. Fecal calprotectin could be a good tool for the molecular screening of active 
intestinal inflammation, because its levels are substantially elevated in IBDs and colorectal  
cancer [167–169]. Furthermore, the amounts of calprotectin in feces have been shown to correlate well 
with the histological lesions caused by continuous inflammation in IBDs [167,168,170] and the tumor 
stage in colorectal cancer [169], indeed with better results than other common plasma biomarkers, such 
as the case of C-reactive protein [167,170]. A reduction in the fecal excretion of calprotectin was 
observed after surgical intervention [169] and oral probiotic administration [171]. Rats fed with a high fat 
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diet in combination with grape seed extract showed lower levels of fecal calprotectin than the control 
animals [172]. 
Although collecting feces is easy and non-invasive, human studies concerning fecal inflammation 
biomarkers are scarce. To our knowledge, there is only one study involving IBDs patients and phenolic 
treatment. In this work, anthocyanin-rich bilberries were administrated to ulcerative colitis patients for 
nine weeks and the results at the end of the study showed a decrease in the fecal levels of calprotectin, 
which increased again when the bilberry treatment was stopped [173]. These results not only show the 
palliative effects of some phenolic compounds in IBDs, but also the inclusion of calprotectin as an 
index of inflammation response after dietary treatment. Exploring the association between phenolic 
compounds and intestinal inflammation through dietary treatment is a promising future approach to  
be considered. 
5. Phenolic Compounds and Gut Microbiota Modulation 
The gastrointestinal tract, especially the large intestine, houses the most abundant and complex 
microbiota in humans. The gut population, composed of approximately 1010–1012 cells per gram of 
intestinal content, participates in several metabolic functions that the host cannot fulfill by itself [174–176]. 
These metabolic functions and their derivative end products depend on the quantitative and qualitative 
features of the gut inhabitants. A harmonious balance in the composition of the gut microbiota has 
been associated with maintaining health and a higher life expectancy accompanied by a satisfactory 
quality of life. An imbalance in the microbial population is known as dysbiosis. Dysbiosis has been 
associated with intestinal and non-intestinal metabolic disorders, which confirms the association 
between the microbiota and non-digestive functions [176]. 
Although full characterization of the microbiota in homeostasis and disease still remains to be 
completed, some trends in its profile could be helpful for discriminating between the two states. A 
lower diversity of bacteria, change in bacteria functionality, and a decrease in the beneficial inhabitants 
together with a major abundance of detrimental opportunistic bacteria seem to be involved in 
metabolic alterations such as obesity and type-2 diabetes, and diseases of the gut such as IBDs and 
colorectal cancer [9,10,73,100,177,178]. An alteration of the microbial equilibrium undermines bowel 
functionality, alters host immunity, and increases susceptibility to pathogen colonization. 
The mechanisms by which the phenolic compounds modulate the gut microbiota still remain to be 
deciphered, but may involve direct and indirect interactions. Phenolic compounds could directly 
stimulate or inhibit bacterial growth. Inhibition is closely related to previously reported antimicrobial 
properties of phenolic compounds and stimulation presumably associated with the capacity of the 
bacteria to metabolize them [131,179]. The antimicrobial activity of phytochemicals has been 
extensively studied because is thought that it is the main cause by which phenolic compounds can 
modify the characteristics of the gut structure population. On the basis of several works [131], it could 
be said that phenolic compounds possess a selectively bacteriostatic or bactericide effect, inhibiting the 
growth of a wide range of potential pathogenic bacteria slightly affecting or even promoting the 
beneficial microbial population. However, it is important to consider the concentration and 
characteristics of the molecule (type of phenolic compound and if it is presented in conjugated or free 
form) because these factors seem to govern the modulation of the desired effects. Indirect implications 
Molecules 2015, 20 17452 
 
 
include complex issues where numerous microbial-host and microbial-microbial interrelationships take 
place. Phenolic metabolites could affect the growth of other bacterial groups and, in turn, the  
over-growth of some bacterial groups could condition the development of others [76,179,180]. 
The prevalence of determinate microbiota members is preferred to others due to the efficacy they 
have shown in ameliorating the gut ecosystem with positive effects at the local and systemic levels. 
For this reason, most studies have focused on the effects of polyphenols on Bifidobacterium and 
Lactobacillus, but there is increasing interest in other emergent bacteria that could be relevant for the 
health of the host [9,101]. Under in vitro conditions, anthocyanins [38], phenolic compounds bound to 
the insoluble cocoa fraction [150], pomegranate extract [45], and soygerm powder [61] have 
stimulated the growth of Lactobacillus and Bifidobacterium. Pomegranate extract and apple pomace 
juice were also capable of increasing Bifidobacterium levels in rodents [111,163]. The Lactobacillus 
count was increased after the administration of apple and red beet pomace juice instead of water in  
rats [110]. Grape seed extract rich in proanthocyanins was able to increase the population of 
Bifidobacterium in healthy adults [125]. Although the phenolic compounds contained in a cocoa 
powder did not prevent the age-induced reduction of Lactobacillus and Bifidobacterium in rats after 
six weeks, they reduced the growth of Bacteroidetes, Staphylococcus, and Clostridium [181]. The latter 
prebiotic effects could also have been related to the possible presence of fiber in the phenolic sources. 
Dietary fiber is known to influence the microbiota profile, especially through the increase in probiotic 
microorganisms [182]. However, other sources deprived of dietary fiber, as in the case of incubation of 
individual compounds [76], green tea phenolic compounds in pigs [81], fiber-free juice [101], 
resveratrol administrated to rats [10], isoflavone supplementation in women [183], and cocoa-isolated 
phenolic compounds in healthy adults [184], have also shown positive effects to favor the increase in the 
number of Bifidobacterium [10,76,183,184], Lactobacillus [10,101,184], and butyrate-producing bacteria 
in parallel with the modulation of growth of bacteria associated with gut dysbiosis [10,76,184]. 
Diet is probably the most easily manipulable factor to modulate the composition of the gut 
microbiota, and the latter results show that phenolic compounds per se are presumably able to interact 
with gut inhabitants and produce changes, most of them toward a healthier profile. However, in a 
recent study by our group [85], no changes were observed in the microbiota composition of healthy 
adults after four weeks of sustained intake of pomegranate juice with a high phenolic content. 
Therefore, the production of the microbial phenolic metabolites catechol and phenylpropionic acid was 
correlated with the presence of a higher percentage of some bacterial groups, supporting the existence 
of phenolic compound-bacteria interrelationships. Despite this fact, the moderate consumption of red 
wine by healthy volunteers over a period of 20 days increased the number of Firmicutes, Bacteroidetes, 
Bifidubacterium, and Prevotella [185]. The Bifidobacterium population also increased in the feces of 
healthy humans after six weeks of sustained intake of blueberry drink [186], basically promoted by the 
higher amounts of some species [187]. 
Recent studies have proposed the use of phenolic-rich sources as a therapeutic strategy to prevent 
and, in some cases, reverse the dysbiosis associated with different pathologies. Obese rodents or 
animals fed with obesogenic diets are common tools for studying the role of the microbiota in the 
metabolic syndrome. The metabolic syndrome includes a series of alterations, such as obesity, 
dyslipidaemia, glycosemia, and loss of insulin sensitivity. Thus, the attenuation of one of the latter 
factors could be considered as a protective factor of type 2 diabetes and cardiovascular diseases. A 
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high Firmicutes/Bacteroidetes ratio has been considered an index of obesity and its depletion a marker 
of successful treatment. However, the results in this context are ambiguous. The reduction in the 
incidence of obesity reflected by lesser weight gain and fat accumulation was observed after treatment 
with quercetin plus resveratrol [84], coffee [188], fiber-free plum [101] and cranberry extract [9], but 
no significant differences were observed after pomegranate peel extract intake by obese mice [163]. 
The majority of the latter phenolic treatments showed a modification of the microbial population with 
respect to their control counterparts, but it was not always encompassed by a decrease in the 
Firmicutes/Bacteroidetes ratio, suggesting the involvement of other bacteria or non-microbiota 
mediated effects. Nevertheless, a positive correlation between body mass index and the 
Firmicutes/Bacteroidetes ratio is still questionable because this parameter has not always been 
described in obesity [99,101,189]. The prevention of obesity is a target factor to reduce the incidence 
of type 2 diabetes, which could be reinforced by the additional effects provided by dietary phenolic 
compounds. For example, the administration of cranberry extract to mice for nine weeks increased the 
relative abundance of Akkermansia ssp., which has been linked with the enhancement of diabetic 
protective effects such as an increase in insulin sensitivity and better inflammatory parameters [9]. 
IBDs have also been associated with a microbial status in which Enterobacteriacea, especially  
E. coli, are more abundant than in the control subjects. The characterization of E. coli has revealed that 
the virulent types were more abundant in biopsy specimens in IBDs patients compared with healthy 
individuals, basically due to the expression of adhesines which facilitate the adherence of the bacteria 
to the epithelium surface [190]. The administration of resveratrol to IBD-induced rats for 25 days 
prevented the over-growth of Enterobacteriaceae, particularly E. coli [10]. Some studies confer the 
phenolic compounds with the in vitro properties of inhibiting the cellular adhesion of harmful bacteria 
with a minimal repercussion on the beneficial members of the gut microbiota [191]. 
All seem to indicate that the gut community responds positively to dietary phenolic compounds 
where the abundance of determinate bacteria could contribute to host health maintenance. After 
phenolic intervention, microbiota changes may by expressed on different taxonomic levels. Lack of 
difference at the phylum level does not necessarily indicate a lack of probiotic effects; sometimes the 
changes are evident at class, family, genus, or species levels [84]. 
Microbiota profile and, thus, microbiota modulation after diet intervention can be studied by 
different techniques, such as fluorescent in situ hybridization (FISH), quantitative PCR-based methods  
(qPCR) [76,101], and high-throughput sequencing; these are among the most widely used. The 
analyses by FISH and qPCR are based on identifying and quantifying specific bacterial groups, defined 
as oligonucleotide probes. For this, in most of the assays, the selected probes depend on the specific 
bacteria of interest in the study and probably some important microbial changes may be omitted if the 
probe is not considered in the study. Other, more sophisticated techniques are based on the 
amplification and pyrosequencing of bacterial 16S ribosomal RNA and allow overall population 
bacterial genoma identification (metagenome) [101,177]. A more in-depth and detailed 
characterization of the whole microbiome provides information regarding changes not only in the 
phylum, class, family, and genus but also specific alterations observed at the species level. In 
summary, the phenolic compounds that may hamper the microbial imbalance in situations of risk of 
disease or those that may prevent dysbiosis by reinforcing beneficial bacteria could be included in 
therapeutic strategies to restore or maintain a healthy profile of the gut microbiota. It remains to be 
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elucidated whether dysbiosis is a cause or consequence of several human pathologies associated with 
the microbiota. 
6. Conclusions and Future Perspectives 
The large intestine is a sophisticated and complex ecosystem where interrelationships among the 
host, microbiota, and its metabolic products (dietary and endogenous products) play a key role in local 
and systemic health. The inter-dependence between the latter factors is so tight that the alteration of 
one of them can govern the behavior of the others, altering the gut homeostasis and, thus, making the 
appearance of disease more likely. 
Dietary phenolic compounds reach the colon in variable amounts, enriching the gut lumen of the 
related metabolites derived from the local microbiota metabolism. Lumen phenolics (parent 
compounds and their metabolites) can actively take part in the innumerable interactions that occur in 
the large intestine. Depending on their nature, diet phenolic compounds apparently enhance the 
generation of beneficial metabolic products and/or hamper the production and effects of detrimental 
luminal compounds, protecting and prolonging gut homeostasis. The mechanisms by which phenolic 
compounds can interact with the gut metabolism may involve interference with enzymatic expression 
and activity, changes in the characteristics of the gut environment, changes in the modulation of the 
signaling pathways responsible for pro-oxidant, inflammatory, and carcinogenic effects, enhancement 
in the protection of the intestinal epithelium from the negative effects of toxic substances, and/or the 
modulation of the microbial population. 
There are still several aspects that require emphasizing. Phenolic compounds undergo active colonic 
microbial transformations, generating intermediate and final related metabolites that could be present 
in the digesta in higher concentrations than their precursors, without necessarily sharing the same 
bioactivity. In this context, studies focused on analyzing the parent compounds in food probably fail to 
estimate the phenomena occurring in the colon correctly. It would be important to identify whether the 
health benefits are associated with the parent compounds or their respective microbial derivatives in 
order to design the correct dietetic or technological strategies to obtain major and better results from 
phenolic dietary therapies. 
Phenolic compounds represent a wide group including several sub-groups that, although they have 
similar characteristics, are not completely equal. Differences in chemical structure, number of 
functional groups, and the combination of different moieties probably lead to these molecules having 
different functions. Despite the information obtained and published over recent years, the effects and 
mechanisms by which phenolic compounds promote changes in the human gut ecosystem are not yet 
completely elucidated. A solution could be partly promoted by the combination of metabolomic 
(characterization of metabolite changes in the gut environment after dietary intervention with phenolic 
compounds or phenol-rich foods), microbiome (gut bacteria collective genome), and metagenomic (for 
the identification of down- or over-expressed proteins involved in microbial activities, whose 
classification thus depends on the function) disciplines to describe a more complete scenario promoted 
by phenolic compounds. 
Given all of the above, the design and performance of more research, especially focused on human 
trials, is encouraged to confirm the efficacy of phenolic compounds at the gut level. The results 
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provided by previous and future studies could be useful to the design of dietary recommendations not 
only to suppress or reduce symptoms in disease but also to provide the healthy population with simple 
tools to promote the maintenance of health. 
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